Why Chemed Stock Is Plummeting Today

Chemed's shares declined 9% after its Q2 earnings missed analyst expectations, with adjusted EPS plummeting 22% despite a 4% sales increase. Both core segments faced significant profitability challenges: Vitas's earnings dropped 24% due to Medicare cap billing limitations, coinciding with its CEO's departure, while Roto-Rooter's net income fell 20% amid rising marketing costs. Compounding concerns, management slashed its 2025 EPS guidance from $25.20 to $22.15, implying a 4% decline from last year's earnings.

Analysis

Chemed (CHE) experienced a significant 9% share price decline following a Q2 earnings report that missed analyst expectations. Despite a 4% increase in total sales, the company's profitability was severely eroded, with adjusted earnings per share (EPS) plummeting by 22%. This negative performance is compounded by a downward revision of the full-year 2025 EPS guidance from $25.20 to $22.15, which implies a 4% decline from the prior year's earnings. Both of the company's core segments are facing substantial headwinds. The Vitas hospice care unit saw its earnings drop 24% due to Medicare cap billing limitations, and its adjusted EBITDA was flat, indicating stagnant underlying profitability even before regulatory impacts. The departure of the Vitas CEO, Nick Westfall, introduces leadership uncertainty to this challenged segment. Simultaneously, the typically stable Roto-Rooter business reported a mere 1% sales growth alongside a 20% contraction in net income, driven by escalating marketing costs attributed to changes in Google's search policies that reduce organic visibility and compel higher ad spend.

Key Decisions for Investors

• Investors should exercise caution due to the dual headwinds of regulatory pressure on Vitas and margin compression from rising marketing costs at Roto-Rooter, which indicate systemic profitability challenges.
• The significant reduction in 2025 EPS guidance, coupled with the unexpected departure of the Vitas CEO, signals heightened operational risk and uncertainty, making it prudent to monitor for signs of stabilization before considering new long positions.
• While the valuation of 20 times free cash flow may seem appealing for a turnaround scenario, the fundamental deterioration across both business segments suggests significant execution risk, and investors should weigh this heavily against the potential for value.